Humuline Nph Patroon (Insulin Human (Rdna))

Humuline Nph Patroon is indicated for the long‑term management of blood glucose in adults with diabetes.

• Type 1 diabetes mellitus (insulin‑dependent).
• Type 2 diabetes mellitus (when oral agents insufficient).
• As part of basal insulin regimen combined with rapid‑acting insulin.
• To provide basal insulin coverage during periods of fasting or between meals.
• May be used in hospital settings for glucose control under physician direction.
• In patients requiring a stable, intermediate‑acting insulin profile to reduce nocturnal hyperglycemia.

• Humuline Nph Patroon delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering endogenous glucose production. The NPH formulation provides a prolonged release, creating an intermediate‑duration basal insulin effect.

Adverse reactions reported with Humuline Nph Patroon are generally consistent with those of other intermediate‑acting insulins.

Common

• Mild hypoglycemia, especially if meals are missed or delayed.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy (localized fat accumulation or loss) at the injection site.
• Transient weight gain due to fluid retention.
• Nausea or headache shortly after injection.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Edema or heart failure exacerbation in susceptible patients.
• Unexplained visual disturbances suggesting acute hyperglycemia.
• Anaphylactic shock requiring emergency medical attention.

When prescribing Humuline Nph Patroon, clinicians should consider several precautionary factors to ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review patient’s history of hypoglycemia unawareness before initiating therapy.
• Adjust dose during periods of illness, pregnancy, or significant weight change.
• Monitor for signs of cardiovascular strain, especially in patients with heart failure.
• Educate patients on proper injection technique to reduce lipodystrophy risk.
• Avoid use in individuals with known hypersensitivity to human insulin or any formulation excipients.

Humuline Nph Patroon may interact with other medications that affect glucose metabolism or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms.
• High‑dose corticosteroids that markedly increase blood glucose.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemia.
• ACE inhibitors or ARBs, which can enhance insulin sensitivity.
• Alcohol consumption, as it can unpredictably affect glucose levels.
• Thyroid hormones, which may alter insulin requirements.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function and insulin clearance.